OS Therapies Inc. Form 8-K Summary
Business Context and Reporting Period
OS Therapies Inc. (OSTX), an emerging growth company incorporated in Delaware, filed this Current Report on Form 8-K on April 9, 2025. The filing documents the results of a Special Meeting of Stockholders held on the same date at the offices of Olshan Frome Wolosky LLP in New York, New York.
Key Financial Metrics
This filing is a corporate governance report regarding a stockholder vote and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial performance metrics.
Material Changes and Voting Results
The primary event reported is the approval of the "Issuance Proposal" by a majority of votes cast. The proposal sought approval for the issuance of common stock upon:
- Conversion of 1,775,750 shares of Series A Senior Convertible Preferred Stock.
- Exercise of certain warrants to purchase common stock.
- Exercise of warrants issued to affiliates of the placement agent and selected dealers.
The issuance was approved to exceed 20% of the common stock outstanding as of December 24, 2024, without regard to conversion or exercise limits. The voting results were as follows:
| Vote Category | Number of Shares |
|---|---|
| Votes For | 11,587,018 |
| Votes Against | 74,984 |
| Abstentions | 11,921 |
| Total Votes Cast | 11,673,923 |
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document is strictly limited to reporting the outcome of the stockholder vote required under NYSE American LLC Company Guide Section 713(a).
Key Facts for Investor Verification
- Capital Structure Impact: Verify the exact number of new shares to be issued following the conversion of 1,775,750 Series A Preferred shares and the exercise of the specified warrants.
- Dilution Analysis: Assess the dilution impact on existing shareholders, as the approved issuance exceeds 20% of the outstanding common stock as of December 24, 2024.
- Warrant Terms: Review the specific terms of the warrants exercised, including any price reset or anti-dilution provisions mentioned in the filing.
- Future Filings: Monitor subsequent filings (e.g., Form 10-Q or 10-K) for the financial impact of this capital raise and the company's updated cash position.